Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India
· Delayed Price · Currency is INR 979.60
+6.65 (0.68%)
Jul 11, 2025, 3:29 PM IST
Zydus Lifesciences Revenue
In the fiscal year ending March 31, 2025, Zydus Lifesciences had annual revenue of 232.42B INR with 18.90% growth. Zydus Lifesciences had revenue of 65.28B in the quarter ending March 31, 2025, with 17.96% growth.
Revenue
232.42B
Revenue Growth
+18.90%
P/S Ratio
4.21
Revenue / Employee
8.63M
Employees
26,921
Market Cap
979.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Mankind Pharma | 122.07B |
| Apollo Hospitals Enterprise | 217.94B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.83B |
| Alkem Laboratories | 129.65B |
Zydus Lifesciences News
- 3 days ago - Jefferies maintains buy on Zydus Lifesciences, sees 15.5% upside on resilient FY26 growth outlook - Business Upturn
- 23 days ago - Zydus completes USFDA inspection at oncology plant with two minor observations, none related to data integrity - Business Upturn
- 4 weeks ago - Stocks to watch on June 12: Zydus Life, Adani Group, Tanla Platforms, HUL, Nazara Tech, MCX in focus - Business Upturn
- 4 weeks ago - Zydus receives USFDA EIR for Ankleshwar API facility with ‘No Action Indicated’ status - Business Upturn
- 4 weeks ago - Zydus receives EIR with VAI classification from USFDA for Dabhasa API facility - Business Upturn
- 5 weeks ago - Top stocks to buy today: Stock recommendations for June 5, 2025 - The Times of India
- 5 weeks ago - Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang - Benzinga
- 5 weeks ago - Zydus secures licensing rights for next-gen immuno-oncology platforms from US-based Agenus - Business Upturn